What type of study is this?

September 10, 2025Open Access

Outcomes of Infants and Young Children With CNS Embryonal Tumors Using Pre‐Irradiation Chemotherapy: A Decade Long Experience

Key Points

The study found a 3-year event-free survival rate of 39.8% for children with CNS embryonal tumors, indicating challenges in management.
Among the 72 children treated, medulloblastoma had a favorable 3-year overall survival rate of 62%, compared to other tumor types.
The analysis utilized both surgery and pre-irradiation chemotherapy, suggesting it as a viable option for younger children with CNS tumors.
Despite lower survival compared to aggressive treatments, moderate-intensity chemotherapy presents a safer alternative in resource-limited settings.

Abstract

Management of infants and young children with embryonal tumors of the central nervous system remains a challenge. We report the outcomes in these children with the strategy of surgery, pre-irradiation chemotherapy, and delayed radiation. Children less than 3 years and diagnosed with medulloblastoma(MB), atypical teratoid rhabdoid tumor(ATRT), embryonal tumor with multilayered rosettes(ETMR), embryonal tumor tumors NOS(ET NOS) and pineoblastoma(PB), underwent standard evaluation and staging. They were treated with maximal safe surgical excision followed by pre-irradiation chemotherapy (cyclophosphamide, etoposide and carboplatin) up to 36 months of age or till disease progression, followed by either craniospinal (standard 35Gy or reduced-dose 23.4 Gy) with boost to a total of 54.8 Gy or focal irradiation depending on attained age, residual tumor, and metastasis. 72 children between January 2011 and December 2022 were eligible for inclusion; medulloblastoma-43 (59.7%), ATRT-9 (12.9%), ET NOS-8 (11.1%), ETMR-8 (11.1%) and PB-4 (5.6%). The median chemotherapy cycles were 6 (range 2-15); 41 children went on to receive RT. For the entire cohort, 3-year event-free survival (EFS) and overall survival (OS) were 39.8% ± 5.8% and 44.8% ± 5.9%. For medulloblastoma, 3-year PFS and OS were 57.4% ± 7.6% and 62% ± 7.5%. Multivariable analysis for survival in medulloblastoma found group 3 metastatic (HR 3.5, 95% CI 1.16-10.99, p = 0.026) and postoperative residual tumor (HR 1.9%, 95% CI 0.52-5.31, p = 0.24) to be significant prognostic factors. Among long-term survivors (n = 27), over 80% have late toxicities requiring intervention. The use of moderate-intensity pre-irradiation chemotherapy is safe and effective in infants and young children with CNS ETs. Despite inferior outcomes compared to high-dose chemotherapy and intraventricular chemotherapy, this strategy could be used in resource-limited settings.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Prasad et al. (Fri,) studied this question.

synapsesocial.com/papers/68c1bd2a54b1d3bfb60edffb https://doi.org/https://doi.org/10.1002/cam4.71128

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper